Alcoholic liver disease other diagnostic studies
|
Alcoholic liver disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Alcoholic liver disease other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Alcoholic liver disease other diagnostic studies |
|
Alcoholic liver disease other diagnostic studies in the news |
|
Risk calculators and risk factors for Alcoholic liver disease other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
Liver biopsy is used to confirm the diagnosis when alcoholic hepatitis is suspected, and to help in guiding medical treatment. Microscopic findings on biopsy that indicate alcoholic hepatitis are: polymorphonuclear infiltration of cells, hepatic necrosis, ballooning hepatocytes, Mallory bodies within cells, and perivenular and perisinusoidal fibrosis.
Other Diagnostic Studies
Liver Biopsy
- Fatty liver
- Macrovesicular fat
- Alcoholic hepatitis
- Polymorphonuclear infiltration
- Hepatic necrosis
- Mallory bodies in hepatocytes
- Perivenular and perisinusoidal fibrosis
- Ballooning hepatocytes
- Steatosis
- Alcoholic cirrhosis
Other diagnostic tests
Biomarkers for assessing fibrosis in patients with alcoholic liver disease:[1]
- FibroTest[2]
- Based on α2-macroglobulin, haptoglobin, GGT, ApoA1 and bilirubin
- FibrometerA[3]
- Based on prothrombin time, α2-macroglobulin, hyaluronic acid and age
- Hepascore[4]
- Based on bilirubin, GGT, α2-macroglobulin, hyaluronic acid , age and gender
2010 AASLD/ACG Alcoholic Liver Disease Guidelines (DO NOT EDIT)[5]
Biopsy : Guidelines (DO NOT EDIT)[5]
| Class I |
| 1. " For patients with a clinical diagnosis of severe alcoholic hepatitis (AH) for whom medical treatment is contemplated, or for those in whom reasonable uncertainty exists regarding the underlying diagnosis, a liver biopsy should be considered. This decision will depend on local expertise and ability in performing a liver biopsy in patients with coagulopathy, the patient’s severity of illness, and the type of therapy under consideration (Level of evidence: C) " |
References
- ↑ Mueller S, Seitz HK, Rausch V (2014). "Non-invasive diagnosis of alcoholic liver disease". World J. Gastroenterol. 20 (40): 14626–41. doi:10.3748/wjg.v20.i40.14626. PMC 4209529. PMID 25356026.
- ↑ Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, Barri-Ova N, Dauvois B, Prévot S, Ngo Y, Munteanu M, Balian A, Njiké-Nakseu M, Perlemuter G, Poynard T (2009). "Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease". Hepatology. 49 (1): 97–105. doi:10.1002/hep.22576. PMID 19053048.
- ↑ Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M, Chaput JC, Poynard T (2005). "Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease". Clin. Gastroenterol. Hepatol. 3 (2): 167–74. PMID 15704051.
- ↑ Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, Ternisien C, Chevailler A, Lunel F (2005). "A novel panel of blood markers to assess the degree of liver fibrosis". Hepatology. 42 (6): 1373–81. doi:10.1002/hep.20935. PMID 16317693.
- ↑ 5.0 5.1 "www.aasld.org" (PDF). Retrieved 2012-10-27.